- Senti Biosciences (SNTI, Financial) has released a Virtual Investor KOL Connect segment featuring a discussion on acute myeloid leukemia (AML).
- The segment highlighted Senti Bio's lead program, SENTI-202, and its clinical and preclinical data.
- Dr. Stephen Strickland and Dr. Kanya Rajangam discussed current treatments and unmet medical needs for AML.
Senti Biosciences, Inc. (SNTI), a clinical-stage biotechnology company, has unveiled a Virtual Investor KOL Connect segment. This online event featured a moderated discussion between Dr. Stephen Strickland, Director of Leukemia Research at the Sarah Cannon Research Institute, and Dr. Kanya Rajangam, President, Head of R&D, and Chief Medical Officer of Senti Bio.
The discussion focused on acute myeloid leukemia (AML), reviewing the current treatment landscape and areas where medical needs remain unmet. A significant part of the conversation highlighted Senti Bio's lead program, SENTI-202, which is gaining attention in the biotechnological field for its potential in AML treatment. Clinical and preclinical data released so far were reviewed during the segment.
SENTI-202, developed using Senti Bio's proprietary Gene Circuit platform, is designed to target hematologic cancers, specifically acute myeloid leukemia (AML). This platform aims to enhance the precision and control of cell and gene therapies, offering new hope for patients with incurable diseases. The program is currently enrolling patients in a Phase I clinical trial.
The Virtual Investor KOL Connect segment is now available for viewing online, offering insights into Senti Bio's innovative approach to AML treatment and the potential of its Gene Circuit platform. Senti Bio continues to advance its pipeline, which includes off-the-shelf CAR-NK cells engineered to target both liquid and solid tumor indications.
